Key Highlights

  • ADMA Biologics (NASDAQ:ADMA) was quoted 23.09% higher at USD 12.90 in premarket trading on November 5, 2026, after third-quarter results released on November 4, 2026.
  • Third-quarter Revenue reached USD 141.1 million, up 5.1% from a year earlier, while ASCENIV revenue rose 30.7% to USD 124.7 million.
  • GAAP Net Income climbed to USD 49.9 million, or USD 0.22 per share, and adjusted EBITDA reached USD 77.3 million with a gross Margin of 71%.
  • Full-year 2026 guidance now calls for at least USD 530 million of revenue, at least USD 180 million of adjusted net income and at least USD 275 million of adjusted EBITDA.

Third-Quarter Results Drive the Move

ADMA Biologics (NASDAQ:ADMA) reported third-quarter 2026 results on November 4, 2026, and the shares were quoted at USD 12.90, up 23.09%, in premarket trading on November 5, 2026, per the premarket quote. According to the company release, total revenue was USD 141.1 million, up 5.1% from the third quarter of 2025 and up 13% from USD 124.4 million in the second quarter. GAAP net income was USD 49.9 million, compared with USD 36.4 million a year earlier, and Diluted Earnings per Share were USD 0.22. Adjusted EBITDA was USD 77.3 million, up about 32% from USD 58.7 million. Management credited accelerating ASCENIV demand.

Mix Shift Toward ASCENIV Lifts Margins

The headline revenue growth of 5.1% hides a sharp change in product mix. ASCENIV, the company's immunoglobulin for primary humoral immunodeficiency, generated USD 124.7 million, up 30.7% year over year and up 21% from the second quarter. BIVIGAM revenue fell 35.2% to USD 15.4 million from USD 23.8 million, and intermediates and other products dropped to USD 0.9 million from USD 15.0 million. Because ASCENIV carries higher margins, Gross Profit reached USD 99.9 million, a gross margin of 71% versus 56% in the prior-year quarter. That is the mechanism behind net income rising about 37% on only modest revenue growth.

Buybacks, Debt and What to Watch

The Balance Sheet showed cash of USD 124.6 million at September 30, 2026, against long-term debt of USD 191.6 million plus a USD 4.2 million current portion. The company repurchased 2.7 million shares in the third quarter and 16.5 million shares year to date, equal to 6.3% of shares outstanding at December 31, 2025, with treasury stock acquisitions of USD 180.3 million over nine months. It remains on track for its previously stated target of at least USD 200 million of repurchases in 2026. Risks include the steep decline in BIVIGAM and intermediates revenue, which weighs on top-line growth, and the fact that a one-day premarket jump can fade once regular trading opens. Investors will watch fourth-quarter ASCENIV Demand and progress toward the full-year targets.

Where Things Stand

The jump at ADMA Biologics (NASDAQ:ADMA) looks driven by earnings quality rather than revenue size: GAAP net income of USD 49.9 million, a 71% gross margin and a raised adjusted earnings outlook, set against modest 5.1% revenue growth. The quoted 23.09% move is a premarket quote on November 5, 2026, not a close, and regular-session trading may differ. The balance of evidence favors a company converting a higher-margin product into profit while shrinking its share count through buybacks. Offsetting that, BIVIGAM weakness and debt of USD 191.6 million remain. The next marker is the fourth-quarter report and whether ASCENIV demand keeps the full-year revenue floor of USD 530 million within reach.